key: cord-0762062-k55zp8u5 authors: Buckley, Jordan E.; Landis, Laura N.; Rapini, Ronald P. title: Pityriasis Rosea-like Rash after mRNA COVID-19 Vaccination: A Case Report and Review of the Literature date: 2022-02-09 journal: JAAD Int DOI: 10.1016/j.jdin.2022.01.009 sha: dc19467186625fb72b3cca79af63379fe044ee09 doc_id: 762062 cord_uid: k55zp8u5 A spectrum of cutaneous reactions to SARs-CoV-2 (COVID-19) vaccines have been reported in the literature.1 We present a case of a pityriasis rosea-like rash occurring after Pfizer COVID-19 vaccination and review cases of pityriasis rosea (PR)/ pityriasis rosea-like eruption (PR-LE) after mRNA COVID-19 vaccine published in the medical literature. Of the 30 cases found, none experienced severe adverse effects and the rash resolved in an average of 5.6 weeks. It is important for physicians to be aware of this self-limited reaction so they can reassure and appropriately counsel patients that it is safe to receive subsequent vaccine doses despite the cutaneous eruption. Additionally, differences in incidence of this reaction after Pfizer and Moderna vaccination may suggest a differing host immune response incited by these vaccines which warrants further investigation. A spectrum of cutaneous reactions to SARs-CoV-2 (COVID-19) vaccines have been reported in 24 the literature. 1 We present a case of a pityriasis rosea-like rash occurring after Pfizer COVID-19 25 vaccination and review cases of pityriasis rosea (PR)/ pityriasis rosea-like eruption (PR-LE) after 26 mRNA COVID-19 vaccine published in the medical literature. Of the 30 cases found, none 27 experienced severe adverse effects and the rash resolved in an average of 5.6 weeks. It is 28 important for physicians to be aware of this self-limited reaction so they can reassure and 29 appropriately counsel patients that it is safe to receive subsequent vaccine doses despite the 30 cutaneous eruption. Additionally, differences in incidence of this reaction after Pfizer and 31 Moderna vaccination may suggest a differing host immune response incited by these vaccines 32 which warrants further investigation. 33 In response to the global COVID-19 pandemic, vaccines were developed at record speed, and 35 as of January 2022, 9.2 billion vaccine doses have been administered worldwide. The 36 Pfizer/BioNTech (BNT162b2) and Moderna (mRNA-1273) vaccines have been widely 37 administered in the United States, accounting for 58% and 38% of vaccinations, respectively. 2 38 These vaccines utilize a novel mRNA technology. Though their initial trials showed only local 39 site reactions, as these vaccines have been distributed, numerous cutaneous side effects have 40 been reported. In contrast, the Johnson and Johnson (Ad26.COV2.S) vaccine, using a non-41 replicating viral vector, has fewer dermatologic side effects reported to date. Among reported 42 cutaneous reactions to mRNA vaccination, delayed large local reaction (a wheal at the injection 43 site after 4 or more days) occurred most commonly. 1 Pityriasis rosea-like eruptions have been reported to both COVID-19 infection and vaccination. 47 Classically PR is a cutaneous eruption that begins with a single erythematous scaly plaque 48 (herald patch) which progresses to multiple plaques or patches that develop diffusely over the 49 trunk and extremities oriented along skin cleavage lines. The pathologic mechanism is (Table I) . 79 syphilis or guttate psoriasis. 12 The history of a herald patch and spontaneous resolution of the 89 rash are helpful distinguishing features. When the presentation is atypical or diagnosis unclear, 90 histopathology can be helpful. In the cases we reviewed, pathology was lacking, as most made 91 the diagnosis of PR based on history and exam findings. 79% of these patients had a herald 92 patch, which is would not be consistent with other disorders in the differential diagnosis. The 93 average duration of the rash was 5.6 weeks. Viral serology for HHV-6/7 was performed in only 94 one case which was negative. 5 All cases of PR after COVID-19 vaccination resolved and none 95 were associated with additional adverse events. 96 Most cases were reported as pityriasis rosea or pityriasis rosea-like eruptions, but 3 were 97 atypical (e.g., purpuric or vesicular). 9 In the literature, PR has been distinguished from PR-like 98 eruption. PR-LE is defined as a reaction to a drug or vaccine, while classic PR is sporadic. -Physicians should recognize that pityriasis rosea-like eruptions following COVID-19 4 vaccinations are benign and self-limited, so they may counsel patients that it is safe to 5 receive subsequent doses. Cutaneous reactions reported after 162 19 vaccination: A registry-based study of 414 cases 163 COVID-19 and vaccination: new keys to understand an old acquaintance Epub ahead of print Pityriasis rosea-like eruption after Pfizer-BioNTech COVID-19 vaccination Pityriasis rosea after administration of Pfizer-180 BioNTech COVID-19 vaccine Pityriasis rosea-like 183 eruptions following vaccination with BNT162b2 mRNA COVID-19 Vaccine Pityriasis rosea developing after COVID-19 vaccination 187 Pityriasis 190 rosea following SARS-CoV-2 vaccination: A case series Pityriasis rosea after mRNA COVID-19 Cutaneous adverse reactions after m-RNA COVID-195 19 vaccine: early reports from Northeast Italy Pityriasis rosea as a cutaneous manifestation of Human herpesvirus-6, 202 -7, and Epstein-Barr virus reactivation in pityriasis rosea during COVID-19 Vaccine-induced pityriasis rosea and pityriasis 205 rosea-like eruptions: a review of the literature Safety and efficacy of the BNT162b2 mRNA covid-208 19 vaccine Efficacy and safety of the mRNA-1273 SARS-CoV-2 210 vaccine